Randomised clinical trial: Efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 4, 2011, Pages 424-431

  Sun, J ^a   Hou, J L ^a   Xie, Q ^b   Li, X H ^c   Zhang, J M ^d   Wang, Y M ^e   Wang, H ^f   Lai, J Y ^g   Chen, S J ^h   Jia, J D ⁱ   Sheng, J F ^j   Chan, H L Y ^k   Wang, J F ^l   Li, M K K ^m   Jiang, M ⁿ   Popescu, M ^o   Sung, J J Y ^k  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^g PRINCESS MARGARET HOSPITAL   (Hong Kong)

^h JINAN INFECTIOUS DISEASE HOSPITAL   (China)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j ZHEJIANG UNIVERSITY   (China)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^l FUDAN UNIVERSITY   (China)

^m TUEN MUN HOSPITAL   (Hong Kong)

ⁿ Roche China Ltd   (China)

^o F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE DISORDER;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHINA; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960565132     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04750.x     Document Type: Article

References (22)

1. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63. (Pubitemid 29489740)
2. Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009; 10: 131-7.
3. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
5. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80. (Pubitemid 30452590)
6. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65. (Pubitemid 44953670)
7. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95. (Pubitemid 44476796)
8. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90. (Pubitemid 43069209)
9. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12. (Pubitemid 44433727)
10. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51. (Pubitemid 350047463)
11. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.
12. Leemans WF, Flink HJ, Janssen HL, et al. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006; 44: 507-11. (Pubitemid 43227874)
13. Vassiliadis T, Patsiaoura K, Tziomalos K, et al. Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12: 2417-22.
14. Danalioglu A, Kaymakoglu S, Cakaloglu Y, et al. Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B. Int J Clin Pract 2004; 58: 659-61. (Pubitemid 39144579)
15. Ersoz G, Akarca US, Gunsar F, et al. Interferon re-treatment for resistance to lamivudine plus interferon treatment. Turk J Gastroenterol 2003; 14: 223-7. (Pubitemid 351676882)
16. Suzuki F, Tsubota A, Akuta N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002; 37: 922-7. (Pubitemid 35423045)
17. Marcellin P, Boyer N, Piratvisuth T, et al. Efficacy and safety of peginterferon alpha-2a in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues-the PegLam cohort. J Hepatol 2006; 44: S187.
18. Shi XF, Guo SH, Yang LZY, et al. Peginterferon alfa-2a for patients with HBeAg-positive CHB who failed prior lamivudine treatment. Hepatol Int 2007; 1: 18.
19. Xu D, Xie Y, Wei L, et al. Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: S266.
20. Marcellin P, Sung J, Piratvisuth T,. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int 2010; 30: 657-68.
21. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
22. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95. (Pubitemid 41007823)